Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H. Rennard SI, et al. Among authors: mcivor a. Int J Chron Obstruct Pulmon Dis. 2016 Aug 17;11:1921-8. doi: 10.2147/COPD.S109661. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27574416 Free PMC article. Clinical Trial.
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI. Martinez FJ, et al. Among authors: mcivor a. Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC. Am J Respir Crit Care Med. 2016. PMID: 27585384 Clinical Trial.
The COPD Foundation Pocket Consultant Guide.
Thomashow B, Crapo J, Yawn B, McIvor A, Cerreta S, Walsh J, Mannino D, Rennard S. Thomashow B, et al. Among authors: mcivor a. Chronic Obstr Pulm Dis. 2014 May 6;1(1):83-87. doi: 10.15326/jcopdf.1.1.2014.0124. Chronic Obstr Pulm Dis. 2014. PMID: 28848814 Free PMC article. Review.
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI. Martinez FJ, et al. Among authors: mcivor a. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC. Am J Respir Crit Care Med. 2018. PMID: 29763572 Clinical Trial.
Treatable traits in the NOVELTY study.
Agustí A, Rapsomaniki E, Beasley R, Hughes R, Müllerová H, Papi A, Pavord ID, van den Berge M, Faner R; NOVELTY Study Investigators. Agustí A, et al. Respirology. 2022 Nov;27(11):929-940. doi: 10.1111/resp.14325. Epub 2022 Jul 21. Respirology. 2022. PMID: 35861464 Free PMC article.
Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort.
Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DM, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chisholm A, Bateman ED; Respiratory Effectiveness Group. Jones RC, et al. Lancet Respir Med. 2014 Apr;2(4):267-76. doi: 10.1016/S2213-2600(14)70008-6. Epub 2014 Feb 13. Lancet Respir Med. 2014. PMID: 24717623 Free article.
89 results